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Abstract 
Background: The aim was to identify susceptibility alleles for infantile hypertrophic pyloric 
stenosis (IHPS) in a pedigree previously linked to IHPS5 on chromosome 16q24. 
Methods: We screened the positional and functional candidate gene FOXF1 by Sanger 
sequencing in a single affected individual.  All family members for whom DNA was available 
were genotyped to determine co-segregation status of the putative causal variant.  
Immunofluorescence studies were performed to compare the cellular localisation of wildtype and 
mutant form of the protein.  Transcriptional activity was compared using a luciferase assay. 
Results: A single novel substitution in FOXF1 (c.416G>A) predicted to result in a missense 
mutation (R139Q) was shown to co-segregate with disease trait.  It was not seen in 560 control 
chromosomes nor has it been reported in ExAC or ESP. The R139Q substitution affects a 
conserved arginine residue within the DNA-binding domain of FOXF1.  The transcriptional 
activity of the mutant FOXF1 protein is significantly reduced in comparison to wild-type.   
Conclusion: These results provide strong evidence that the R139Q substitution in FOXF1 causes 
IHPS in this family and imply a novel pathological pathway for the condition. They further 
support a role for FOXF1 in the regulation of embryonic and neonatal development of the gastro-
intestinal tract.   
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Introduction 
Infantile hypertrophic pyloric stenosis (IHPS, MIM # 179010) is the most common 
inherited cause of gastrointestinal obstruction in the first few months of life with an incidence of 
1-8 per 1000 live births in the Caucasian population.  It typically affects infants 3-12 weeks after 
birth1 with clinical features including projectile vomiting, weight loss and dehydration.  
Treatment is by pyloromyotomy, which was introduced a century ago (see review by 
MacMahon, 20062).   
A genetic predisposition is clearly established, although environmental factors are also 
important2.  A prone sleeping position has been proposed and investigated as a potential cause of 
IHPS. This theory stemmed from the observation of parallel decreasing incidences of IHPS and 
sudden infant death syndrome (SIDS)3.  However, the most recent longitudinal study does not 
support this theory4.  There is population-based evidence supporting bottle-feeding as a risk 
factor5.  Pre- and postnatal exposure to erythromycin have been proposed as risk factors for IHPS 
but studies are not consistent although the risk associated with postnatal exposure appears to be 
more significant6-9.  
IHPS shows familial aggregation and represents a paradigm for the multifactorial sex-
modified threshold model of inheritance, with affected males outnumbering females in a 4:1 
ratio10.  IHPS is predicted to be oligogenic, determined by two or three loci of moderate effect 
estimated to confer individual genotype relative risks (GRRs) of up to 511.  
IHPS has been associated with several genetic syndromes12;13 and chromosomal 
abnormalities14;15.  Autosomal dominant monogenic forms of IHPS have also been reported in 
several extended pedigrees16-18.  Five loci for familial IHPS have been identified: IHPS1 (the 
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NOS1 gene on chromosome 12q24)19; IHPS2  (chromosome 16p12-p13)16; IHPS3 (chromosome 
11q14-q22)20; IHPS4 (chromosome Xq23)20; and IHPS5 (chromosome 16q24)21.   
IHPS5 (OMIM #612525) was identified through a SNP-based whole genome linkage 
scan of a single extended family with multiple cases of IHPS; the family also described in this 
paper.  Chromosome 16 was the only chromosome for which a significant LOD score (>3) was 
achieved, assuming autosomal dominant inheritance with reduced penetrance.  A shared 
haplotype on one chromosome extends across 4.2Mb of the linked region and is present in all 
affected individuals and obligate carriers on whom genotyping was performed (7 cases and two 
obligate carriers; Supplemental Table S1, online).  This region of chromosome 16 contains a 
cluster of FOX genes: FOXF1; FOXC2; and FOXL1.  FOX proteins are transcription factors 
characterised by the classic winged-helix-turn-helix (wHTH) ~110 amino acid binding domain.  
In most cases the protein  is composed of three α-helices (H1-H3), two to four β sheets and two 
loops (the “wings”, W1 and W2) (see review by Carlsson and Mahlapuu, 200222.  FOX proteins 
tend to bind as monomers with H3 acting as the recognition helix to fill the major groove of the 
target DNA whilst W2 interacts with the minor groove23;24.  Previous work has shown that 
mutations affecting the amino acid sequence of the W2 domain can affect transactivation 
ability25.   
In humans, mutations in FOXF1 have been associated with a range of GI tract 
abnormalities including duodenal stenosis, annular pancreas, congenital short bowel and 
intestinal malrotation26.  It has been shown in mice that during organogenesis, Foxf1 is expressed 
in splanchnic mesoderm which gives rise to the muscular components of the GI tract, such as the 
pyloric smooth muscle27;28.  There is evidence that Foxf1 is a downstream effector of the Sonic 
Hedgehog pathway with respect to lung, stomach and intestinal development.  These data 
6 
 
support FOXF1 as an excellent positional and functional candidate gene for IHPS. 
The aim of our work was to identify susceptibility alleles in the linked region on 
chromosome 16.  Here we report the identification of a missense variant in FOXF1 which 
segregates with disease in the large extended IHPS family previously mapped to 16q24.3. We 
demonstrate that the variant reduces the transcriptional efficacy of the resulting protein in vitro. 
We suggest that this variant may cause IHPS in this family by affecting downstream expression 
of other genes. 
 
Results 
Fine-mapping of associated haplotype 
We first attempted to fine map the IHPS5 region using three microsatellite markers.  Figure 1 
shows the genotypes for all SNPs within the associated haplotype and the three microsatellites 
genotyped for this report.  Genotyping of the microsatellite markers did not reduce the size of the 
critical region.  As such, all three FOX genes remained functional and positional candidates 
requiring further investigation. 
 
Candidate gene analysis 
FOXF1 
Re-sequencing of individual III.9 identified a single novel missense variant in exon 1 of FOXF1 
(NM001451.2); c.416G>A (counting the A of the start codon as position 1), p.R139Q (counting 
7 
 
the start codon as residue number 1).  The patient was heterozygous for this substitution 
(Supplementary Figure S1, online; see also Supplementary Table S2 for other known SNPs 
identified).  Analysis using Mutation Taster predicted this amino acid change to be disease 
causing.  Polyphen also predicts this change to be “Probably Damaging” (with a score of 1.00). 
The presence of the A allele was shown to create an MspA1I site (the recognition site for 
MspA1I is CMGCKG; in the wildtype, this sequence is CGGCGG which would not be 
recognised by the enzyme; the mutation changes this sequence to CAGCGG which is recognised 
by the enzyme and the fragment is cut).  Individuals homozygous for the wild type G allele have 
a single fragment 531bp in length; GA heterozygotes have two fragments, one 531bp, the other 
442bp in size; individuals who are AA homozygotes would have just the 442bp fragment.  All 
affected members genotyped (III.1, III.9, III.14, IV.1, IV.2 and IV.4), either through a restriction 
digest or through direct Sanger sequencing, were heterozygous for the variant (GA).  Both 
obligate carriers (III.2 and III.11) were also heterozygous for the mutation (Figure 1).  All 
unaffected, non-carriers genotyped (II.4, II.5, III.3, III.5, III.6, III.7, III.10, III.13, III.15, and 
IV.5) were homozygous for the wild type allele.  The remaining family members could not be 
genotyped due to unavailability of DNA. 
This variant has not been reported in either ExAC or the Exome Sequencing Project and we did 
not identify it through sequencing of 560 control chromosomes. 
FOXC2 and FOXL1 
Re-sequencing identified a number of SNPs but no putative causal variants (Supplementary 
Tables S3 and S4, online). 
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FOXF1 trans-activation activity 
The p.R139Q substitution found in individual III.9 affects a conserved arginine residue within 
the DNA-binding domain of FOXF1 and is predicted to impair protein function. FOXF1 has 
been shown previously to act as a transcriptional activator29;30. In order to compare the trans-
activation activity of FOXF1 and FOXF1-p.R139Q, we used a luciferase reporter construct, 
pGHV-luc, containing control elements from the 5’-flanking region of growth hormone variant30. 
Transient transfection of FOXF1 constructs into HepG2 cells did not activate a promoter-less 
pGL3 reporter. The pGHV-luc reporter showed increased, basal activity in HepG2 cells. Co-
transfection with FOXF1 caused robust activation of pGHV-luc (~5-fold), whereas the FOXF1-
p.R139Q variant showed no significant effect on luciferase activity (Figure 2). 
 
FOXF1 protein localisation 
The lack of trans-activation activity of FOXF1-p.R139Q suggests that this variant represents a 
loss of function mutation. To exclude the possibility that the p.R139Q substitution causes mis-
targeting of the FOXF1 protein, we generated N-terminal, myc epitope-tagged fusion proteins for 
both FOXF1 and FOXF1-p.R139Q by sub-cloning into pCMV-Myc. Constructs were transiently 
transfected into HEK-293 cells and protein localisation detected by immunofluorescence using 
an anti-myc antibody. Nuclei were counter-stained with Hoechst dye. Both FOXF1 and FOXF1-
p.R139Q proteins were localised to the nucleus, but not the cytoplasm (Figure 3), demonstrating 
that the p.R139Q variant is stable and correctly targeted to the nucleus. 
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Discussion 
In this study, we have identified a novel nucleotide substitution (c.416G>A) in FOXF1 which 
segregates with disease and carrier status in a single family with IHPS and reduces the trans-
activation ability of the protein.  Though this appears to be a rare, family-specific mutation, it 
does provide important new scientific information on IHPS and FOXF1 function.   
Family IHPS78 has a number of interesting features.  The two known ‘obligate carriers’ share 
with affected individuals a single copy of the disease-associated haplotype within which lies the 
single copy of the mutant allele c.416G>A.  The presence of obligate carriers suggests that the 
mutation is not fully penetrant or that there may be variable expressivity.  Diagnosis of IHPS can 
usually be made on clinical examination with a typical history of forceful vomiting.  This can be 
confirmed by either upper gastrointestinal contrast study or ultrasound examination which is now 
routinely performed.  IHPS can be considered as a continuous trait as measured by the 
hypertrophy of the pyloric musculature. Babies with IHPS can have variable degree of vomiting 
determined by the severity/degree of the pyloric muscle hypertrophy and obstruction. Infants 
with diagnostic features of IHPS on radiological examinations yet without significant symptoms 
have been reported.  It is likely that mild cases of IHPS exist who never require medical 
intervention and resolve spontaneously by 3-4 months of age.  IHPS is a complex condition 
which arises from interaction between multiple predisposing genes and environmental factors. 
The obligate carriers in this family most likely represent mild cases of IHPS who may not have 
had all the necessary or sufficient genetic and/or environmental triggers required during the 
appropriate timeframe to develop clinically diagnosable IHPS.  It is plausible that affected 
individuals share genetic variants at other loci that may interact with the FOXF1 mutation 
leading to disease expression whilst obligate carriers do not share these other interacting variants.  
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However, it should be pointed out that this family did not show linkage to any of the other 
reported familial IHPS loci so any interaction is likely to be with variants at other loci.  For 
example, a genome wide association (GWA) study has identified three variants significantly 
associated with IHPS which have implicated the genes MBNL1 and NKX2-531.  Two of these 
variants were shown to be associated in an independent Northern European replication cohort32.  
The variant associated with NKX2-5 was also significantly associated in a Chinese cohort33.  
More recently a further locus was implicated by GWA analyses that indicate a possible role for a 
gene on chromosome 11q23.334 and there is the suggestion that variants in RET may play a 
contributory role in IHPS35.  Clearly IHPS has a highly complex, multifactorial mode of 
inheritance involves multiple predisposing alleles and different biological pathways, as well as 
environmental cues.  Modelling these interactions is an interesting challenge that may become 
possible as we understand more about the aetiology. Typically there is a male to female 
predominance in IHPS but this is not seen in this family (there are 5 males affected and 3 
females; of the obligate carriers, one is male and one is female).  This is also observed in other 
large pedigrees with multiple affecteds in our resource, i.e. in families with many cases of IHPS 
there are more equal numbers of male and female cases.  In our resource of 358 trios, the ratio of 
male to female cases is approximately 5:1 whilst amongst our 141 multiple case pedigrees, it is 
around half this at ~5:2.  It is not understood why more males are affected by IHPS than females 
but it seems likely that males are somehow more biologically predisposed and that their risk 
threshold is lower (one of the linked loci, IHPS4, is on the X chromosome which may yet 
explain the gender bias).  However, when there is a genetic variant which is sufficiently severe, 
the likelihood of females also passing their higher risk threshold increases and therefore families 
occur with multiple cases and although still more males are affected, the difference is not so 
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apparent.  In this situation, gender has less effect on disease risk.  It is plausible that the 
biological significance of alternative genetic variants differ considerably depending upon the 
gene (and pathway) affected leading to differing levels of penetrance.  Whether the same 
equality of gender distribution is seen in other families with multiple cases of IHPS may depend 
on which gene contains the causal variant. 
Results of our study confirm an important role for FOXF1 in the development and function of 
upper gastrointestinal tract. The substitution results in a change in the amino acid sequence 
(p.R139Q). This residue is conserved in murine Foxf1 as well as many FOX proteins including 
those encoded by the chromosome 16 cluster (Supplementary Figure S2, online).  This residue is 
also conserved in FOXF1 homologues across several species (data not shown except for mouse 
but available via HomoloGene).  The exact structure of the FOXF1 protein has not been 
compiled but based on known structures of other related FOX proteins and on amino acid 
sequence alignment22;25, residue 139 of FOXF1 is likely to form part of the W2 domain. This 
region of the protein is responsible for binding to the shallow groove of the target DNA. We 
show that c.416G>A (p.R139Q) affects the normal function of the FOXF1 protein by the reporter 
gene assay. The trans-activation activity of the mutant FOXF1 is statistically significantly 
reduced in comparison to the wildtype and is comparable to that of the empty vector. Our 
immunofluorescence studies show that the mutant FOXF1 is localising normally to the nucleus. 
Our hypothesis therefore is that the mutant FOXF1 trafficks normally to the nucleus but binds to 
the target binding sequence with reduced efficacy.  How this eventually leads to IHPS has not 
been answered by this study but will continue to be part of our future work. 
It has been established that murine Foxf1 is a target gene of the Hedgehog (Hh) pathway36;37 
which is a key component of the development of the vertebrate gut.  Haploinsufficiency of Foxf1 
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causes lung and gut malformations37.  During embryonic development, Foxf1 is primarily 
expressed in the splanchnic mesoderm from which the smooth musculature of the GI tract is 
derived22.  In   humans, inactivating mutations and microdeletions of FOXF1 have been 
associated with alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) 
and a range of malformations in the heart, lung and GI tract including intestinal malrotation and 
duodenal stenosis26. None of these features is present in any member of family IHPS78 and GI 
tract abnormalities are not seen in all patients with ACDMPV.  This may be because this family 
only has a missense mutation in FOXF1 which does not lead to complete inactivation of the 
protein.  However, recently a missense mutation at the same site (R139L) was identified in three 
siblings with ACDMPV, the segregation of which appeared to be consistent with paternal 
imprinting of FOXF138.  Our results are not consistent with this but differential patterns of 
imprinting have been reported between different tissues39 which could partly explain the 
contrasting results with regards to severity of disease and mode of inheritance.   
Two other genes in the chromosome 16q24.1 cluster of FOX genes are FOXC2 and FOXL1.  We 
could not exclude them based on our haplotype analysis so we also re-sequenced these genes in 
IHPS patients but did not find any putative causal mutations which segregated with disease.  We 
acknowledge that there are other genes in this region which we did not re-sequence and it is 
possible that the variant we have identified in FOXF1 is in linkage disequilibrium with the actual 
causal variant which may reside in another gene.  However, FOXF1 is the best functional 
candidate in the region and the evidence from our luciferase assay supports the hypothesis that 
the p.R139Q mutation in FOXF1 is causal in this family. 
There appear to be potentially many downstream targets of FOXF1 including growth hormone 
variant (GHV), as utilised within our study during the luciferase assay, but also including 
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members of the S1P/S1PR1 signalling pathway40 and genes involved in lung development and 
angiogenesis41.  In mice, it has been shown that FoxF1 acts either independently or as part of a 
reciprocal pathway with BMP4 to trigger expression of Gata4, which itself forms part of a 
family of transcription factors important in development42.  It is often thought that the smooth 
muscle hypertrophy seen in IHPS is a result of failure of relaxation which suggests that FOXF1 
normally inhibits the action of a downstream target. The identification of the specific targets of 
FOXF1 affected in this instance will be a major focus of our immediate future work.  
There still remain many unanswered questions regarding the age and tissue specific nature of 
IHPS and function of FOXF1 in relation to this which are beyond the scope of this preliminary 
study but will need to be investigated further.  
In summary, we have identified FOXF1 as a new disease gene for IHPS and suggest a novel 
biological pathway to be investigated to further our understanding of the disorder.  The co-
existence of a mutation in FOXF1 and IHPS also provides further evidence for a role for FOXF1 
in embryonic, and possibly neonatal, development of the GI tract.   
 
Materials and Methods 
Subjects and Samples 
A large Irish Caucasian family was ascertained as previously described16; all affected individuals 
had undergone pyloromyotomy for IHPS (see Figure 1 for pedigree structure).  The study was 
approved by the University College London Hospital Ethics Committee and relevant local 
regional committees.  Informed consent was obtained from all participating individuals. 
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Fine-mapping of associated haplotype 
Three microsatellite markers were selected to reduce the size of the associated haplotype.  These 
markers were: D16S520, D16S3074 and D16S3077.  Oligonucleotide primers were designed to 
amplify these microsatellites in all members of the family on whom DNA was available.  Primer 
details were taken directly from UniSTS (primer and protocol details available on request).  
Supplementary Table S1 (online) contains a list of the SNPs and microsatellites which comprise 
the associated haplotype and their relative positions.    
 
Candidate gene analysis 
FOXF1 
The FOXF1 gene has two coding exons totalling 1140 nucleotides.  Oligonucleotide primers 
were designed to amplify these two exons and the exon-intron boundaries in three fragments 
(primer details available on request).  A single affected individual from family 78 (III.9) was re-
sequenced to identify putative causal variants.  Mutation Taster43 and Polyphen244 were used to 
predict the biological effect of any putative causal variant identified.  The ClustalW alignment 
tool was used to compare protein sequences45.   
The remaining family members from whom DNA was available were genotyped for the 
identified putative causal variant using a restriction digest utilising the restriction enzyme 
MspA1I and/or direct Sanger sequencing of the surrounding area. 
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This variant was screened for in the resource of affected IHPS patients (549 individuals, both 
sporadic and familial cases) and in 280 controls by outsourcing to KBiosciences (now part of 
LGC Genomics). 
Approximately 5kb of genomic DNA, extending from 500bp upstream of the start of the 5’UTR 
of FOXF1 to 500bp downstream of the end of the 3’UTR of FOXF1, was re-sequenced in 58 
affected individuals from the largest 58 IHPS pedigrees in our resource.  This re-sequencing was 
outsourced to Polymorphic DNA Technologies, Inc.  
FOXC2 and FOXL1 
FOXC2 has a single coding exon totalling 1683 nucleotides and FOXL1 has a single coding exon 
totalling 3189 nucleotides.  These exons plus 500bp upstream and downstream were re-
sequenced in a single affected individual from the 39 families consistent with linkage to 16q24.3 
(as identified through the previous genome-wide linkage studies20;21; again primers are available 
on request).  This re-sequencing was performed in-house.  A putative causal variant in FOXL1 
was genotyped in remaining family members using the restriction enzyme DrdI. 
 
Expression constructs 
A FOXF1 expression construct was the kind gift of Prof. P. Carlsson29. The FOXF1-p.R139Q 
(FOXF1-mut) mutation was synthesised by Eurofins MWG Operon and verified by sequencing. 
The FOXF1 and FOXF1-mut constructs were sub-cloned into both pCDNA3 and pCMV-Myc 
(Clontech). Details of mutagenesis and sub-cloning are available on request. A FOXF1 luciferase 
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reporter construct, pGHV(-158/+57)-luc, containing upstream sequences from Growth Hormone 
Variant was the kind gift of Dr. S. Handwerger30. 
 
Luciferase assays 
HepG2 cells (ATCC Number HB 8065) were maintained in DMEM containing 10% foetal calf 
serum, penicillin and streptomycin and grown at 37°C in a humidified atmosphere of 5% CO2. 
Cells were plated at 25000 cells per well so that they were between 40-70% confluent 24 hours 
later. Transfections were performed in sextuplicate using Polyfect (QIAGEN, Manchester, UK) 
according to manufacturer’s instructions. Each well contained 50ng of the reporter construct, 
500ng of pCDNA3 (containing FOXF1, FOXF1-mut or beta-galactosidase as control) and 10ng 
of pRL-TK (Promega, Southampton, UK) for normalization. An empty luciferase vector (pGL3, 
Promega) was used as a control. Normalized luciferase activity was measured after 48 hours 
using a Dual-Luciferase assay system (Promega). Results are a representative example from one 
experiment. Statistical analysis was performed using GraphPad Prism software. Samples were 
compared by one-way ANOVA with Tukey’s post-comparison test. Values are expressed as 
means ±SEM. 
 
Immunofluorescence 
HEK-293 cells (ATCC Number CRL-1573) were cultured and transfected using the same 
conditions as above, except that cells were plated onto Poly-D-lysine coated glass cover slips in a 
24-well plate and 2µg of pCMV-Myc DNA was used. Cells were fixed in PBS containing 4% 
17 
 
paraformaldehyde 24h after transfection. The myc epitope tag was detected using a rabbit-anti-
myc antibody (Abcam ab9106) at 1:500 dilution and a goat-anti-rabbit Alexa Fluor 488 
(Invitrogen) secondary antibody at 1:200 dilution. Nuclei were counterstained with Hoechst 
33258. 
 
Supplemental Data Description 
Supplementary data contains four tables pertaining to: the SNPs and microsatellites which 
constitute the associated haplotype across chromosome 16q24.3; and details of the variants 
identified through re-sequencing of FOXF1, FOXC2 and FOXL1.  Two figures are also within 
the Supplementary data: a figure showing the wildtype sequence around the variant and the 
variant in heterozygous state; and a figure showing conservation of the residue affected by the 
variant in FOXF1 across the different FOX proteins. 
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Figure titles and legends 
 
Figure 1. Schematic showing the pedigree structure of family IHPS78 and the SNP and 
microsatellite genotypes across the linked region.  Squares indicate males; circles females; a 
line through indicates that the individual is deceased.  Shaded individuals are affected with IHPS.  
The disease-associated haplotype is indicated by the brown bar.  Other haplotypes are of varying 
style simply to differentiate between them; there is no significance to the colour or style.  Those 
individuals who are heterozygous for the c.416G>A mutation are indicated with a black asterisk. 
 
Figure 2. Trans-activation of pGHV-luc by wild type and mutant FOXF1. Wild type FOXF1 
(black fill) induces robust activation of pGHV(-158/+57)-luc (pGHV), but FOXF1-p.R139Q 
(grey fill) does not. Background activity is seen with an empty pCMV-myc vector (white fill). 
Neither FOXF1 construct affects the activity of a promoter-less pGL3 vector (pGL3). Values are 
expressed as relative luciferase units (RLU), normalised to pRL-TK and represent the mean ± 
SEM of 6 replicates. † P<0.01 
 
Figure 3. Sub-cellular localisation of wild type and mutant FOXF1. Myc-epitope tagged 
FOXF1 proteins were detected in HEK-293 cells by immunofluorescence using a rabbit-anti-
myc antibody and goat-anti-rabbit Alexa Fluor 488 secondary antibody (B,E). Nuclei were 
counter-stained with Hoechst 33258 (A,D). FOXF1 localisation appears nuclear in the merged 
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images (C), as expected. FOXF1-p.R139Q localisation also appears nuclear in the merged 
images (F) and is not affected by the missense substitution.  
